Surrozen submits FDA IND for SZN-8141 in diabetic macular edema

PUBT · 1d ago
Surrozen submits FDA IND for SZN-8141 in diabetic macular edema
  • Surrozen submitted an IND application to the FDA to begin clinical testing of SZN-8141 for diabetic macular edema.
  • DUET Phase 1b/2a trial expected to start by year-end 2026; initial data targeted for H2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Surrozen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080830PRIMZONEFULLFEED9822467) on September 08, 2026, and is solely responsible for the information contained therein.